cefprozil 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
antibiotics, cefalosporanic acid derivatives 556 92665-29-7

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • cefprozil
  • cefprozile
  • cephprozyl
  • cefprozil hydrate
  • Molecular weight: 389.43
  • Formula: C18H19N3O5S
  • CLOGP: -1.87
  • LIPINSKI: 0
  • HAC: 8
  • HDO: 4
  • TPSA: 132.96
  • ALOGS: -3.42
  • ROTB: 5
  • Status: OFP
    • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
1 g O

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 4 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 0.06 mg/mL Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 73 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 42.88 µM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 90 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution) 0.21 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 2.90 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.59 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 1.20 hours Lombardo F, Berellini G, Obach RS

Approvals:

DateAgencyCompanyOrphan
Dec. 23, 1991 FDA

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Drug hypersensitivity 79.47 30.63 52 897 310635 63177438
Tubulointerstitial nephritis and uveitis syndrome 31.11 30.63 5 944 240 63487833
Idiopathic urticaria 30.78 30.63 5 944 257 63487816

FDA Adverse Event Reporting System (Male)

None

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Drug hypersensitivity 86.44 27.35 57 1310 298859 79444162
Urticaria 32.04 27.35 26 1341 185175 79557846
Idiopathic urticaria 31.80 27.35 5 1362 181 79742840
Tubulointerstitial nephritis and uveitis syndrome 28.86 27.35 5 1362 330 79742691

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC J01DC10 ANTIINFECTIVES FOR SYSTEMIC USE
ANTIBACTERIALS FOR SYSTEMIC USE
OTHER BETA-LACTAM ANTIBACTERIALS
Second-generation cephalosporins
FDA CS M0003827 Cephalosporins
FDA EPC N0000175488 Cephalosporin Antibacterial
CHEBI has role CHEBI:36047 antibacterial drugs

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Acute otitis media indication 3110003
Haemophilus Influenzae Acute Otitis Media indication 19021002
Infection of skin AND/OR subcutaneous tissue indication 19824006
Bronchitis indication 32398004 DOID:6132
Streptococcal tonsillitis indication 41582007
Upper respiratory infection indication 54150009
Acute bacterial sinusitis indication 75498004
Tonsillitis indication 90176007 DOID:10456
Acute Moraxella catarrhalis bronchitis indication 195722003
Acute bacterial bronchitis indication 233598009
Streptococcus pyogenes infection indication 302809008
Infective otitis media indication 312218008
Infection due to Staphylococcus aureus indication 406602003
Acute exacerbation of chronic bronchitis indication 425748003
Moraxella Catarrhalis Acute Otitis Media indication 703469002
Pneumococcal Acute Otitis Media indication
Streptococcus Pneumoniae Bronchitis indication
Haemophilus Influenzae Chronic Bronchitis indication
Streptococcus Pneumoniae Chronic Bronchitis indication
Moraxella Catarrhalis Chronic Bronchitis indication
Haemophilus Influenzae Bronchitis indication
Pyrexia of unknown origin off-label use 7520000
Acute nephropathy contraindication 58574008
Factor II deficiency contraindication 73975000
Pseudomembranous enterocolitis contraindication 397683000




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 2.7 acidic
pKa2 9.72 acidic
pKa3 7.63 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
Penicillin-binding protein 1A Enzyme WOMBAT-PK

External reference:

IDSource
4020058 VUID
N0000148083 NUI
D00261 KEGG_DRUG
19552 RXNORM
C0053882 UMLSCUI
CHEBI:3506 CHEBI
CHEMBL3301800 ChEMBL_ID
CHEMBL3184906 ChEMBL_ID
CHEMBL276568 ChEMBL_ID
DB01150 DRUGBANK_ID
C052018 MESH_SUPPLEMENTAL_RECORD_UI
5281006 PUBCHEM_CID
12219 IUPHAR_LIGAND_ID
4W0459ZA4V UNII
4382 MMSL
73619 MMSL
d00073 MMSL
003623 NDDF
387538005 SNOMEDCT_US
96054007 SNOMEDCT_US
4020058 VANDF
121123-17-9 SECONDARY_CAS_RN

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Cefprozil HUMAN PRESCRIPTION DRUG LABEL 1 0093-1077 TABLET, FILM COATED 250 mg ORAL ANDA 25 sections
Cefprozil HUMAN PRESCRIPTION DRUG LABEL 1 0093-1077 TABLET, FILM COATED 250 mg ORAL ANDA 25 sections
Cefprozil HUMAN PRESCRIPTION DRUG LABEL 1 0093-1078 TABLET, FILM COATED 500 mg ORAL ANDA 25 sections
Cefprozil HUMAN PRESCRIPTION DRUG LABEL 1 0093-1078 TABLET, FILM COATED 500 mg ORAL ANDA 25 sections
Cefprozil Human Prescription Drug Label 1 16714-396 POWDER, FOR SUSPENSION 125 mg ORAL ANDA 25 sections
Cefprozil Human Prescription Drug Label 1 16714-396 POWDER, FOR SUSPENSION 125 mg ORAL ANDA 25 sections
Cefprozil Human Prescription Drug Label 1 16714-397 POWDER, FOR SUSPENSION 250 mg ORAL ANDA 25 sections
Cefprozil Human Prescription Drug Label 1 16714-397 POWDER, FOR SUSPENSION 250 mg ORAL ANDA 25 sections
Cefprozil Human Prescription Drug Label 1 16714-398 TABLET, FILM COATED 250 mg ORAL ANDA 25 sections
Cefprozil Human Prescription Drug Label 1 16714-398 TABLET, FILM COATED 250 mg ORAL ANDA 25 sections
Cefprozil Human Prescription Drug Label 1 16714-399 TABLET, FILM COATED 500 mg ORAL ANDA 25 sections
Cefprozil Human Prescription Drug Label 1 16714-399 TABLET, FILM COATED 500 mg ORAL ANDA 25 sections
Cefprozil HUMAN PRESCRIPTION DRUG LABEL 1 50090-1188 TABLET, FILM COATED 500 mg ORAL ANDA 26 sections
Cefprozil Human Prescription Drug Label 1 50090-1710 TABLET, FILM COATED 500 mg ORAL ANDA 25 sections
Cefprozil Human Prescription Drug Label 1 50090-1710 TABLET, FILM COATED 500 mg ORAL ANDA 25 sections
Cefprozil Human Prescription Drug Label 1 50090-1739 TABLET, FILM COATED 500 mg ORAL ANDA 24 sections
CEFPROZIL HUMAN PRESCRIPTION DRUG LABEL 1 52959-300 TABLET 500 mg ORAL ANDA 14 sections
CEFPROZIL HUMAN PRESCRIPTION DRUG LABEL 1 53217-031 TABLET 500 mg ORAL ANDA 14 sections
CEFPROZIL HUMAN PRESCRIPTION DRUG LABEL 1 54868-5756 TABLET 500 mg ORAL ANDA 14 sections
Cefprozil HUMAN PRESCRIPTION DRUG LABEL 1 54868-5757 POWDER, FOR SUSPENSION 250 mg ORAL ANDA 14 sections
CEFPROZIL HUMAN PRESCRIPTION DRUG LABEL 1 55648-712 TABLET, FILM COATED 250 mg ORAL ANDA 20 sections
CEFPROZIL HUMAN PRESCRIPTION DRUG LABEL 1 55648-713 TABLET, FILM COATED 500 mg ORAL ANDA 20 sections
Cefprozil Human Prescription Drug Label 1 57237-034 POWDER, FOR SUSPENSION 125 mg ORAL ANDA 25 sections
Cefprozil Human Prescription Drug Label 1 57237-034 POWDER, FOR SUSPENSION 125 mg ORAL ANDA 25 sections
Cefprozil Human Prescription Drug Label 1 57237-035 POWDER, FOR SUSPENSION 250 mg ORAL ANDA 25 sections
Cefprozil Human Prescription Drug Label 1 57237-035 POWDER, FOR SUSPENSION 250 mg ORAL ANDA 25 sections
Cefprozil Human Prescription Drug Label 1 57237-036 TABLET, FILM COATED 250 mg ORAL ANDA 24 sections
Cefprozil Human Prescription Drug Label 1 57237-036 TABLET, FILM COATED 250 mg ORAL ANDA 24 sections
Cefprozil Human Prescription Drug Label 1 57237-037 TABLET, FILM COATED 500 mg ORAL ANDA 24 sections
Cefprozil Human Prescription Drug Label 1 57237-037 TABLET, FILM COATED 500 mg ORAL ANDA 24 sections